The drug has the side effect of nausea, based on data from preliminary human subject safety (Phase 1) trials. About 60% of patients experience nausea and a small percentage suffer severe vomiting. Additionally, some peripheral nerve dysfunction was noted in experimental animals exposed to the drug, and in the phase 1 human subject studies about 10% of subjects reported mild tingling sensations in hands or feet. The plan is now to test the drug in patients who have failed conventional therapy for certain leukaemia’s; the goal of the trial is to determine whether reductions in tumour load similar to those observed in experimental animals will occur. In the doses used in this trial, the drug is unlikely to change life expectancy of these terminal patients. 15 reference by Harvard styleView less